Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

Stock Information for NexGel Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NexGel Inc

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
Protalix BioTherapeutics Letter to Stockholders
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.